Application of tirofiban in reperfusion treatment of acute ischemic stroke
10.3760/cma.j.issn.1673-4165.2020.02.006
- VernacularTitle:替罗非班在急性缺血性卒中再灌注治疗中的应用
- Author:
Xu CAO
1
;
Fuling YAN
Author Information
1. 东南大学附属中大医院神经内科，南京 21009
- From:
International Journal of Cerebrovascular Diseases
2020;28(2):113-118
- CountryChina
- Language:Chinese
-
Abstract:
Tirofiban is a selective non-peptide glycoprotein Ⅱb/Ⅲa receptor inhibitor that reversibly inhibits fibrinogen-dependent platelet aggregation and subsequent thrombosis. Thrombosis caused by platelet activation plays a vital role in the occurrence and development of ischemic cerebrovascular events. Some studies have evaluated the use of tirofiban in intravenous thrombolysis and endovascular therapy. Although the optimal dose, conditions of use, and target patients have not been fully identified, the good tolerability of tirofiban and its efficacy in improving recanalization and long-term functional outcomes have been validated. This article reviews the mechanism of tirofiban and its application in the treatment of acute ischemic stroke reperfusion.
